


AML-1217



1. Papapanou NM, et al. *N Engl J Med*. 2016; 375:900-11. Issa et al. *Leukemia*. 2012; 3:2482-95. Issa et al. *Blood*. 2025; 146(Suppl 1):1764. 4. Erba et al. *Hemaphys*. 2025; 9(Suppl 1):S136. 5. Zeidan et al. *Blood*. 2024; 144(Suppl 1):214. 6. Quora Oncology Inc. 2025; KOMZIT11 (zifentibon) prescribing information, 7. Collins and Hens. *Curr Opin Cancer Biol*. 2024; 34(3):435-61. 8. Lu et al. *Cancer Cell*. 2025; 132(1):92-107. 9. Ferreira et al. *Oncogene*. 2016; 35(23):3079-82. 10. Jeong et al. *Nat Genet*. 2014; 46(1):17-23. 11. Wang et al. *Blood*. 2025; 100(1):254-64. 12. Chowdhury et al. *EMBO Rep*. 2023; 24(12):463-43. 13. Schmidt et al. *Leukemia*. 2019; 33(12):2505-2516. 14. Wang et al. *Cell*. 2019; 177(1):105-116. 15. Wang et al. *Blood*. 2019; 34(5):499-512. 16. Wang et al. *Cancer Discov*. 2023; 13(3):724-45. 17. Lin et al. *Blood Adv*. 2021; 5(6):1719-28. 18. Ranshaw et al. 2025; 114(2):202-19. 19. Jeong et al. 2014; 46(1):17-23. 20. Wang et al. 2025; 147(8):2388-96.